New drug combo shows promise for Hard-to-Treat cancers

NCT ID NCT06049212

Ongoing Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 23 times

Summary

This early-stage trial tests a new drug, MK-2870, alone or with pembrolizumab (with or without chemotherapy) in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check safety and find the right dose. About 30 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Aichi Cancer Center ( Site 0006)

Nagoya, Aichi-ken, 464-8681, Japan
Kanagawa Cancer Center ( Site 0004)

Yokohama, Kanagawa, 241-8515, Japan
Kansai Medical University Hospital ( Site 0007)

Hirakata, Osaka, 573-1191, Japan
National Cancer Center Hospital ( Site 0001)

Chuo-ku, Tokyo, 104-0045, Japan
National Cancer Center Hospital East ( Site 0002)

Kashiwa, Chiba, 277-8577, Japan
National Hospital Organization Shikoku Cancer Center ( Site 0008)

Matsuyama, Ehime, 791-0280, Japan
Shizuoka Cancer Center ( Site 0005)

Nagaizumi-cho,Sunto-gun, Shizuoka, 411-8777, Japan

Conditions

Explore the condition pages connected to this study.

NON SMALL CELL LUNG CANCER PROGRAMMED CELL DEATH 1 LIGAND 1(PDL1, PD-L1) PROGRAMMED CELL DEATH 1 LIGAND 2 (PDL2, PD-L2) PROGRAMMED CELL DEATH-1 (PD1, PD-1) SOLID TUMORS